Asia Pacific Iron Deficiency Anemia Therapy Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2023 –2030 |
Market Size (Base Year) |
USD 480.65 Billion |
Market Size (Forecast Year) |
USD 1,856.30 Billion |
CAGR |
|
Major Markets Players |
>亚太缺铁性贫血治疗市场,按疗法(肠外铁疗法和口服铁疗法)、治疗领域(炎症性肠病、肾病、妇产科、充血性心力衰竭(CHF)、肿瘤科和其他)、人群(成人、儿科和老年人)、最终用户(医院、家庭护理、专科中心、其他)、分销渠道(医院药房、网上药房、零售药房)划分 - 行业趋势和预测到 2030 年。
亚太地区缺铁性贫血治疗市场分析及规模
贫血是当今最常见的血液疾病之一。静脉注射铁剂因其改善了透析以外的治疗质量而得到广泛使用。全球糖尿病患者数量不断增加,老龄化人口不断增加,这反过来又推动了缺铁性贫血治疗的采用。大量研究支持在医院环境中使用口服铁剂疗法替代静脉注射治疗,预计也将增加口服铁剂疗法在人群中的采用率。
Data Bridge Market Research 分析了 2023-2030 年预测期内缺铁性贫血治疗市场的增长率。在上述预测期内,缺铁性贫血治疗市场的预期复合年增长率约为 18.4%。2022 年市场价值为 4.8065 亿美元,到 2030 年将增长至 18.563 亿美元。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
亚太地区缺铁性贫血治疗市场范围和细分
报告指标 |
细节 |
预测期 |
2023 至 2030 年 |
基准年 |
2022 |
历史岁月 |
2021(可定制为 2015 - 2020) |
定量单位 |
收入(百万美元)、销量(单位)、定价(美元) |
涵盖的领域 |
治疗(肠外铁剂治疗和口服铁剂治疗)、治疗领域(炎症性肠病、肾病、妇产科、充血性心力衰竭 (CHF)、肿瘤科及其他)、人群(成人、儿科和老年人)、最终用户(医院、家庭护理、专科中心及其他)、分销渠道(医院药房、网上药房、零售药房) |
覆盖国家 |
亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 其他地区 |
涵盖的市场参与者 |
Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Covis Pharma GmbH (U.S.), PHARMACOSMOS A/S (Denmark), Vifor Pharma Management Ltd. (Switzerland), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India) |
Market Opportunities |
|
Market Definition
Iron deficiency anemia is a type of anemia that occurs when the body's iron stores are reduced. An inadequacy of healthy red blood cells cause anemia. RBCs supply oxygen to human tissues. Iron is important in the production of haemoglobin. Haemoglobin deficiency shows lack of oxygen in the body. It's essential to keep your iron levels in check. Consumption of iron-rich foods such as meat, vegetables, fruits, and cereals can help to treat or prevent iron deficiency. Vitamin C can help to prevent iron deficiency
Asia-Pacific Iron-Deficiency Anemia Therapy Market Dynamics
Drivers
- Rising Incidences of Chronic Kidney Disease
According to the records of National Kidney Foundation, Inc., the two primary causes of chronic kidney disease are diabetes and hypertension. Much of this growing burden of chronic disease is anticipated to be observed in Asia, the most populous continent with a population of >4.5 billion people. There is a major variation in CKD prevalence (7.0%–34.3%) across Asia. We estimate that up to around 434.3 million people have CKD across the Eastern, Southern and South-East regions of Asia, with most of the disease burden observed in China and India. It is anticipated that the incidence of chronic kidney cases will rise across highly economic countries, such as India and China which infers an increase in the aged population over the upcoming years.
- Growing Adoption of Oral Iron Therapy
The oral iron therapy is anticipated to witness huge growth during the forecast period due to the factors such as rise in the patient population suffering from anemia and anemia-causing diseases. In addition to this, an increasing number of research that supports the use of oral iron therapy as a substitute for intravenous treatments in hospital settings is also anticipated to increase the adoption of oral iron therapy among people, thus boosting the segment growth.
Opportunities
- Increase in Anaemia
According to the records of the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anaemia in Asia-Pacific. Rising incidence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, liver disorders, thyroid diseases, cancer, and inflammatory bowel diseases, is a primary factor helping in the growth of the market for intravenous iron. The World Health Organization expected that iron deficiency anemia took the lives of 273,000 people in 2004. Around 45% were Southeast Asian, 31% African, 9% Eastern Mediterranean, 4% Oceania, and 3% European. Out of all anemia cases, about 97% are found in middle-income countries. Thus, it creates opportunity for the market growth.
- Increasing Incidence of Cancer
A rising number of cancer patients tend to develop iron deficiency anemia. Common types of cancer that are widely associated with anemia includes bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer. Lung and breast tumors have been specified with the highest prevalence of anemia among solid tumors. Hematologic malignancies such as lymphoma, leukemia, and multiple myeloma produce abnormal blood cells that as a result harm the immune system and cause anemia. Cancer treatments such as chemotherapy and radiation therapy also increase anemia in cancer patients. This creates more opportunity in the market.
Restraints/Challenges
- Serious Effects of Iron Supplements
There are few adverse effects that are related with the intake of iron drugs. Common effects of include digestive problems such as loss of appetite, constipation, nausea, stomach aches, and vomiting. The overdose of these drugs may also lead to tiredness or weakness, shallow or rapid breathing, convulsions, fatigue, bluish skin, pale skin or fingernails. Thus, this hampers the market growth.
This iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Asia-Pacific Iron-Deficiency Anemia Therapy Market
COVID-19 疫情扰乱了静脉注射铁药物的生产和供应,但是,制造商和政府为满足需求而采取的举措不断增加,促进了静脉注射铁药物市场的增长。除此之外,许多研究表明,Covid-19 感染具有导致急性肾损伤 (AKI) 和 CKD 的巨大风险,这反过来又刺激了对用于治疗 CKD 相关贫血的静脉注射铁药物的需求。卫生当局建议,患有急性肾损伤的 COVID-19 患者应经常接受检测,因为他们患 CKD 的风险高于其他人。因此,COVID-19 对市场增长产生了重大影响。
亚太地区缺铁性贫血治疗市场范围
缺铁性贫血治疗市场根据治疗、治疗领域、人口、分销渠道和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。
治疗
- 肠外铁疗法
- 口服铁剂疗法
治疗领域
- 炎症性肠病
- 肾脏
- 妇产科
- 充血性心力衰竭 (CHF)
- 肿瘤学
- 其他的
人口
- 成年人
- 儿科
- 老年
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
缺铁性贫血治疗市场区域分析/见解
对缺铁性贫血治疗市场进行了分析,并按上述治疗、治疗领域、人群、分销渠道和最终用户提供了市场规模洞察和趋势。
缺铁性贫血治疗市场报告涉及的主要国家 包括亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太地区其他地区 (APAC)。
中国在市场上处于领先地位,因为医疗保健系统的质量和管理、科学家对贫血药物的研究和开发活动日益增多。此外,认知度的提高、政府机构的投资不断增加以及仿制药企业的存在也引领着市场的增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外,在提供国家数据预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和亚太地区缺铁性贫血治疗市场份额分析
缺铁性贫血治疗市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对缺铁性贫血治疗市场的关注有关。
缺铁性贫血治疗市场的主要参与者包括:
- Teva Pharmaceutical Industries Ltd.(以色列)
- 赛诺菲(法国)
- 辉瑞公司(美国)
- 葛兰素史克公司 (英国)
- 诺华公司(瑞士)
- 拜耳公司(德国)
- Cipla Inc.(美国)
- 雅培(美国)
- AbbVie Inc.(美国)
- 太阳制药工业有限公司 (印度)
- Aurobindo Pharma(印度)
- 鲁冰花(印度)
- Hikma Pharmaceuticals PLC(英国)
- Covis Pharma GmbH(美国)
- PHARMACOSMOS A/S(丹麦)
- Vifor Pharma Management Ltd.(瑞士)
- Orion 公司 (芬兰)
- Pharmacosmos A/S(丹麦)
- Shield Therapeutics(英国)
- Advanz 制药 (英国)
- Alkem Labs(印度)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.